Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-TACE vs c-TACE in HCC
NCT05093920Phase 1Unknown
- Sponsor
- Sohag University
- Start
- Jan 2022
- Primary completion
- Dec 2023
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of doxorubicin in hepatocellular carcinoma (HCC), sponsored by Sohag University. Primary endpoint: Tumor size. Status: unknown.
02
Drugs
doxorubicin
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05093920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05093920.